Sandoz Submits Third Biosimilar Application To FDA
The U.S. Food and Drug Administration has accepted a biologics license application from Novartis-owned Sandoz Inc. for a biosimilar that would help cancer patients receiving chemotherapy fight off infection, the drugmaker...To view the full article, register now.
Already a subscriber? Click here to view full article